Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Retained Earnings (2016 - 2025)

Sangamo Therapeutics has reported Retained Earnings over the past 16 years, most recently at -$1.5 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 80.56% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached -$1.5 million, up 80.56%, while the annual FY2025 figure was -$1.5 million, 80.56% up from the prior year.
  • Retained Earnings for Q4 2025 was -$1.5 million at Sangamo Therapeutics, up from -$1.6 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at $714000.0 in Q1 2021 and troughed at -$1.6 billion in Q3 2025.
  • A 5-year average of -$656.7 million and a median of -$894.9 million in 2021 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: surged 118.65% in 2021 and later plummeted 140190.2% in 2022.
  • Year by year, Retained Earnings stood at -$956.3 million in 2021, then dropped by 20.11% to -$1.1 billion in 2022, then surged by 99.6% to -$4.6 million in 2023, then tumbled by 63.87% to -$7.5 million in 2024, then soared by 80.56% to -$1.5 million in 2025.
  • Business Quant data shows Retained Earnings for SGMO at -$1.5 million in Q4 2025, -$1.6 billion in Q3 2025, and -$1.5 million in Q2 2025.